论文部分内容阅读
急性白血病及恶性淋巴瘤,由于对抗癌药敏感性很高,所以常常成为新抗癌药Ⅱ期临床研究的对象。这些肿瘤有治愈的可能性,对急性非淋巴细胞白血病(ANLL)多首选以柔红霉素(DM)和阿糖胞苷(Ara—C)为主的联合化疗,而对非何杰金淋巴瘤(NHL)则首选以阿霉素(ADM)、环磷酰胺(CPM)、长春新碱(VCR)、etoposide(VP)等为核心的联合化疗。新抗癌药只是在上述药物治疗无效或者治疗后复发的病例才被进行Ⅱ期临床研究。部分新抗癌药在这种情况下所以能发生疗效,是和上述药物在临床中无交叉耐药性的缘故。目前,是在相当不利的条件下来试验新抗癌药疗效的。在日本,正在研究中的新抗癌药有具有新
Acute leukemia and malignant lymphomas are often used as phase II clinical studies for new anticancer drugs because of their high sensitivity to anticancer drugs. These tumors have the potential to heal. For acute non-lymphocytic leukemia (ANLL), combination chemotherapy with daunorubicin (DM) and cytarabine (Ara-C) is preferred, but non-Hodgkin lymph For cancer (NHL), combination chemotherapy with doxorubicin (ADM), cyclophosphamide (CPM), vincristine (VCR), and etoposide (VP) is the first choice. The new anticancer drugs were only phase II clinical trials when the above drugs failed to cure or relapse after treatment. Some new anti-cancer drugs in this case can therefore have therapeutic effects, and these drugs have no cross-resistance in the clinical reason. At present, the efficacy of new anticancer drugs is tested under quite unfavorable conditions. In Japan, there are new